Publications by authors named "Igor Vivanco"

Claim this Profile
A
AKT as a Therapeutic Target in Cancer.
Khine N Myint, Igor Vivanco

Curr Top Microbiol Immunol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulated expression promotes increased ciliogenesis and cell invasion phenotypes.
Eleanor Hargreaves, Rebecca Collinson, Andrew D Jenks, Adina Staszewski, Athanasios Tsalikis, Igor Vivanco

Life Sci Alliance· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF.
Nuria Gutierrez-Prat, Hedwig L Zuberer, Luca Mangano, Zahra Karimaddini, Luise Wolf, Igor Vivanco

Life Sci Alliance· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting un-MET needs in advanced non-small cell lung cancer.
Niamh Coleman, Alice Harbery, Sara Heuss, Igor Vivanco, Sanjay Popat

Lung Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine.
Niamh Coleman, Justin T Moyers, Alice Harbery, Igor Vivanco, Timothy A Yap

Pharmgenomics Pers Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.
Elizabeth C Smyth, Georgios Vlachogiannis, Somaieh Hedayat, Alice Harbery, Sanna Hulkki-Wilson, Igor Vivanco

Gut· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.
Evon Poon, Tong Liang, Yann Jamin, Susanne Walz, Colin Kwok, Igor Vivanco

J Clin Invest· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity.
Eleftherios Kostaras, Teresa Kaserer, Glorianne Lazaro, Sara Farrah Heuss, Aasia Hussain, Igor Vivanco

Br J Cancer· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors in AKTion: ATP-competitive vs allosteric.
Glorianne Lazaro, Eleftherios Kostaras, Igor Vivanco

Biochem Soc Trans· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.
Shayna Stein, Rui Zhao, Hiroshi Haeno, Igor Vivanco, Franziska Michor

PLoS Comput Biol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
Barbara Oldrini, Wan-Ying Hsieh, Hediye Erdjument-Bromage, Paolo Codega, Maria Stella Carro, Igor Vivanco

Nat Commun· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IQGAP1 controls tight junction formation through differential regulation of claudin recruitment.
Barbara E Tanos, Andres E Perez Bay, Susana Salvarezza, Igor Vivanco, Ingo Mellinghoff

J Cell Sci· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A kinase-independent function of AKT promotes cancer cell survival.
Igor Vivanco, Zhi C Chen, Barbara Tanos, Barbara Oldrini, Wan-Ying Hsieh

Elife· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death.
Nicholas A Graham, Martik Tahmasian, Bitika Kohli, Evangelia Komisopoulou, Maggie Zhu, Igor Vivanco

Mol Syst Biol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Igor Vivanco, H Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes

Cancer Discov· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor inhibitors in oncology.
Igor Vivanco, Ingo K Mellinghoff

Curr Opin Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation.
Igor Vivanco, Daniel Rohle, Matthias Versele, Akio Iwanami, Daisuke Kuga

Proc Natl Acad Sci U S A· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency.
Li Peng, Ting-Ting Wu, Jason H Tchieu, Jun Feng, Helen J Brown, Igor Vivanco

J Gen Virol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.
Selvaraju Veeriah, Barry S Taylor, Shasha Meng, Fang Fang, Emrullah Yilmaz, Igor Vivanco

Nat Genet· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Lucia Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco

J Clin Invest· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition.
Shasha Meng, Tali Arbit, Selvaraju Veeriah, Ingo K Mellinghoff, Fang Fang, Igor Vivanco

Cell Cycle· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Selvaraju Veeriah, Cameron Brennan, Shasha Meng, Bhuvanesh Singh, James A Fagin, Igor Vivanco

Proc Natl Acad Sci U S A· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
Rameen Beroukhim, Gad Getz, Leia Nghiemphu, Jordi Barretina, Teli Hsueh, Igor Vivanco

Proc Natl Acad Sci U S A· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
Jing Jiao, Shunyou Wang, Rong Qiao, Igor Vivanco, Philip A Watson

Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN.
Igor Vivanco, Nicolaos Palaskas, Chris Tran, Stephen P Finn, Gad Getz

Cancer Cell· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis